Literature DB >> 1676367

A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

T M MacDonald1, R F Jeffrey, S Freestone, M R Lee.   

Abstract

To clarify the contribution made by the renin-angiotensin system activation to the short lived hypotensive response to fenoldopam, the haemodynamic effects of a combination of fenoldopam (100 mg) and enalapril (5 mg) were compared with fenoldopam alone, enalapril alone and placebo in a balanced, randomised, double blind, single dose study in eight hypertensive patients. Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia. Enalapril caused a more gradual fall in blood pressure (onset 2 h) without a reflex tachycardia. The combination of drugs produced greater reductions in blood pressure sustained for a longer period than fenoldopam alone and with a more rapid onset than enalapril alone. In combination the hypotensive effects of fenoldopam and enalapril were clearly additive and not synergistic. Activation of the renin-angiotensin system does not antagonise significantly the hypotensive effect of fenoldopam.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676367     DOI: 10.1007/bf00315201

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.

Authors:  T M MacDonald; R F Jeffrey; A L Muir; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

3.  Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.

Authors:  H O Ventura; F H Messerli; E D Frohlich; I Kobrin; W Oigman; F G Dunn; R M Carey
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

4.  Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

5.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

Authors:  R A Hahn; J R Wardell; H M Sarau; P T Ridley
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

6.  Comparative study of once-daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension.

Authors:  J G Kayanakis; L Baulac
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

7.  Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.

Authors:  Z Glück; L Jossen; P Weidmann; M P Gnädinger; E Peheim
Journal:  Hypertension       Date:  1987-07       Impact factor: 10.190

8.  Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526.

Authors:  D M Ackerman; A L Blumberg; J P McCafferty; S S Sherman; J Weinstock; C Kaiser; B Berkowitz
Journal:  Fed Proc       Date:  1983-02

9.  The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans.

Authors:  M B Murphy; R R Weber; K Nelson; L I Goldberg
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

10.  The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; G Martin; D Redman; S Hasan; P Sever
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

View more
  2 in total

Review 1.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 2.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.